Results 191 to 200 of about 205,975 (308)

Synthetic biology-inspired development of live attenuated influenza vaccines. [PDF]

NPJ Vaccines
Zhang Q, Cheng J, Hou J, Su Y, Li L, Tong L, Li J, Shen Q, Wang Z, Wu M, Li Z, Wang Q, Zhang Y, Sun R, Si L.   +14 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

A qualitative study of vaccination behaviour amongst female Polish migrants in Edinburgh, Scotland [PDF]

, 2019
Bielecki, Braczkowska, Braczkowska, Brydak, Corcoran, Czarkowski, D.R. Gorman, Donaldson, Dubé, European Centre for Disease Prevention and Control, Forster, Fournet, Ganczak, Ganczak, Ganczak, Gorman, Jaroszewicz, Jaroszewska, Jayaweera, Jorgensen, K. Bielecki, K.G. Pollock, Kanitz, Korczynska, L.J. Willocks, Larson, Larson, Larson, Larson, Larson, McCann, Mixer, Mrozek-Budzyn, Mrozek-Budzyn, Mrozek-Budzyn, Napolitano, Owsianka, Pollock, Sawada, Sim, Sime, Zarobkiewicz, Żuk   +42 more
core   +1 more source

Fel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy

Allergy, EarlyView.
This study investigates the allergenicity and immunogenicity profile of a novel plant‐derived Fel d 1 bioparticle (eBP). Fel d 1 eBP promotes immune tolerance by redirecting allergic Th2 responses toward Th1 and IL‐10–producing regulatory pathways, including Bregs.
Janice A. Layhadi, Liliana Cifuentes Gutierrez, Sean T. Keane, William Fulton, Nichell A. Samson, Lily Y. D. Wu, Paulina Filipaviciute, Prista Hikmawati, Oleksandra Fedina, Ana Jimenez‐Gil, Stephen R. Durham, Guy Scadding, Guy Tropper, Louis‐Philippe Vézina, Patrick Colin, Ronald van Ree, Mohamed H. Shamji   +16 more
wiley   +1 more source

Effectiveness of live-attenuated and inactivated influenza vaccines against influenza in 2-17-y-old children, United States, 2022-2025. [PDF]

Hum Vaccin Immunother
Kitano T, Yoshida S.
europepmc   +1 more source

Sustaining Local Production of Influenza Vaccines: A Global Study of Enabling Factors Among Vaccine Manufacturers. [PDF]

Vaccines (Basel)
Chadwick C, Nannei C, Sparrow E, Ampofo W, Flahault A, Berkley S.   +5 more
europepmc   +1 more source

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

Acta Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner, Despina D. Briana, Gian Carlo Di Renzo   +2 more
wiley   +1 more source

Assessing Risk Thresholds in Controlled Human Infection Models (CHIM)

Bioethics, EarlyView.
ABSTRACT Controlled Human Infection Models (CHIMs) are a type of clinical trial involving deliberately exposing human volunteers to an infectious agent. Compared to studies of natural infection, CHIMs offers distinctive benefits, from the ability to study presymptomatic infection to a direct assessment of the efficacy of vaccines and therapeutics in a ...
Alexa Nord‐Bronzyk, Barnaby Young, Jerry Menikoff, Julian Savulescu, G. Owen Schaefer   +4 more
wiley   +1 more source

Influenza vaccines promote humoral and cellular immune responses: a randomized, double-blind, phase 3 trial. [PDF]

Nat Commun
Rodríguez-Guilarte L, Méndez C, Reyes A, Rios M, Román F, Moreno-Tapia D, Cabrera A, Rivera DB, Gutiérrez-Vera C, Palacios PA, Schilling A, Aljaro S, Bascur F, Rojas Á, Del Río C, Astudillo P, Perez CM, Perez L, Oyonarte M, Fernández Vásquez PE, Feijoo RM, Beltrán Campos D, Tovar De Sousa C, Castejón A, Grandón S, Villarroel M, Jara P, Twele L, Angélica Domínguez M, González-Aramundiz JV, Álvarez-Figueroa MJ, Yang W, Xin Q, Carreño LJ, Calvo M, Bueno SM, Peñaloza HF, González PA, Kalergis AM.   +38 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source